Status:
COMPLETED
Remote Outpatient Temperature Monitoring for Early Detection of Febrile Neutropenia After Chemotherapy
Lead Sponsor:
Augusta University
Collaborating Sponsors:
University of Georgia
Conditions:
Acute Myeloid Leukemia (AML)
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Febrile neutropenic patients are at high risk for developing sepsis and other infections which often necessitates acute admission to the Intensive Care Unit (ICU) and are associated with high mortalit...
Eligibility Criteria
Inclusion
- Patients who have acute myeloid leukemia (AML) and are candidates for consolidation chemotherapy with high dose cytarabine (HiDAC) after successful remission induction chemotherapy
- Both male and female
- Age 18 years and older
Exclusion
- Patients who have already developed febrile neutropenia during their hospitalization for their consolidative cycle of chemotherapy will not be eligible for monitoring for that cycle; however, these patients will be able to participate in subsequent cycle if they do not develop febrile neutropenia during their subsequent HiDAC hospitalization.
- • If a patient is admitted to the hospital between cycles of chemotherapy for reasons other than febrile neutropenia or its sequelae, they will be taken off study for that cycle and data not collected while they are admitted
Key Trial Info
Start Date :
December 16 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 31 2024
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT04081753
Start Date
December 16 2019
End Date
July 31 2024
Last Update
September 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Augusta University Medical Center
Augusta, Georgia, United States, 30912